Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Cancer Institute (NCI) National Eye Institute (NEI) National Heart, Lung, and Blood Institute (NHLBI) National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Biomedical Imaging and Bioengineering (NIBIB) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute on Deafness and Other Communication Disorders (NIDCD) National Institute of Dental and Craniofacial Research (NIDCR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute on Drug Abuse (NIDA) National Institute of Environmental Health Sciences (NIEHS) National Institute of General Medical Sciences (NIGMS) National Institute of Mental Health (NIMH) National Institute of Neurological Disorders and Stroke (NINDS) National Institute of Nursing Research (NINR) National Institute on Minority Health and Health Disparities (NIMHD) National Library of Medicine (NLM) Fogarty International Center (FIC) National Center for Complementary and Alternative Medicine (NCCAM) National Center for Advancing Translational Sciences (NCATS) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
Funding Opportunity Title	Limited Competition: Restoration of New Investigator Pilot Projects Adversely Affected by Hurricane Sandy (R21)
Activity Code	R21 Exploratory/Developmental Research Grant Award
Announcement Type	New
Related Notices	July 30, 2014 - Notice of Annual Reporting Requirements and Revised Financial Closeout Requirements for NIH Administrative Supplements Awarded to Recover Losses Due to Hurricane Sandy under the Disaster Relief Appropriations Act. See Notice NOT-OD-14-112. August 28, 2013 - See Notice NOT-OD-13-106. Notice of Special Terms and Conditions for NIH Hurricane Sandy Recovery Awards. July 3, 2013 - See Companion RFA-OD-13-007. Limited Competition: Extramural Research Facilities Restoration Program: Hurricane Sandy Disaster Relief (C06).
Funding Opportunity Announcement (FOA) Number	RFA-OD-13-005
Companion Funding Opportunity	RFA-OD-13-006, S10 Biomedical Research Support Shared Instrumentation rants RFA-OD-13-007, C06 Research Facilities Construction Grant RFA-OD-13-008, R24 Resource-Related Research Projects RFA-OD-13-199, Administrative Supplement
Number of Applications	See Section III. 3. Additional Information on Eligibility.
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.095
Funding Opportunity Purpose	This Funding Opportunity Announcement (FOA) solicits applications from research institutions damaged as a result of Hurricane Sandy for the purpose of supporting recovery and restoration of new and early stage investigator pilot research and data destroyed or damaged as a result of the hurricane. Benefits of this award are restricted to the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia.

Posted Date	April 15, 2013
Open Date (Earliest Submission Date)	May 19, 2013
Letter of Intent Due Date(s)	May 19, 2013
Application Due Date(s)	June 19, 2013, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)	Not Applicable
Scientific Merit Review	August 2013
Advisory Council Review	October 2013
Earliest Start Date	November 1, 2013
Expiration Date	June 20, 2013
Due Dates for E.O. 12372	Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

In October 2012, Hurricane Sandy devastated parts of the Northeast United States. The storm affected numerous communities, including the biomedical communities located in this region. NIH is issuing several funding opportunities specifically to help restore and re-build the research and research infrastructure in the biomedical research institutions damaged as a result of Hurricane Sandy. Benefits of this award are restricted to the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia. This funding opportunity will be funded through funds received under the Disaster Relief Appropriations Act of 2013 (P.L. 113-2).

In keeping with NIH’s longstanding support of new and early stage investigators, this Funding Opportunity Announcement (FOA) solicits applications from research institutions damaged as a result of Hurricane Sandy for the purpose of supporting the recovery and restoration of pilot research and data destroyed or damaged as a result of the hurricane by new and early stage investigators. Restoration of these data will assist new and early stage investigators to rebuild the data and infrastructure needed to again be poised to launch competitive independent research careers. NIH expects that recipients of awards from this FOA will be able to redevelop the pilot data needed to submit an NIH research project grant application within one or two years.

Using the NIH Exploratory/Development Grant (R21) funding mechanism, this FOA focuses on new and early stage investigators with projects in early and conceptual stages (i.e. pilot projects), that could provide a basis for more extended research.

This is a one-time funding opportunity. Applicants must describe how they will accommodate the resources they are requesting in the event that major renovations or re-establishment of resources is required in order to perform the proposed research. Applications also should describe efforts undertaken since the hurricane to recover and restore research and data.

Principal investigators must be new or early stage investigators as defined by NIH (see NIH New and Early Stage Investigator Policies).

Funds provided by the NIH through this FOA cannot duplicate nor overlap with reimbursement provided by FEMA, under a contract for insurance, or by self-insurance.

Funds will be provided in a single award with a 24-month budget and project period. No-cost extensions will not be available. Therefore the applicant must assure that the scope of work proposed and outlays of awarded funds can be completed within this 24-month period.

Applications must meet the following criteria to be considered responsive:

• Applicant institution was damaged as a result of Hurricane Sandy defined as, and limited to, the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia.
• A letter from the institution is included in the application that verifies that pilot research data existed prior to the hurricane and includes a description of the extent of the damage, destruction or loss resulting from the hurricane, including staff time, research materials, resources, supplies, and preliminary data. Also, the letter must confirm that the application does not request any funding that overlaps with FEMA, under a contract for insurance or self insurance payments. The letter must be signed by an institutional Signing Official.
  

Applications meeting any of the following criteria will be considered non-responsive and will be not proceed to peer review:

• Applicant institution does not meet the definition of an institution impacted by Hurricane Sandy.
• A letter of support from the institution was: (a) NOT included in the application, (b) did not verify that pilot research data existed prior to the hurricane, (c) does not describe the extent of damage, destruction or loss including staff time, research materials, resources, supplies, and preliminary data, or (d) did not include a statement that the application does not request any funding that overlaps with FEMA, under a contract for insurance or self insurance payments.

Funding Instrument	Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Application Types Allowed	New The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards	The number of awards is contingent upon funds received by NIH from the Disaster Relief Appropriations Act and the submission of a sufficient number of meritorious applications. The NIH intends to commit up to approximately $2 million; awards will be made in FY2014. The extent and severity of damages on the research and directly related to Hurricane Sandy will be used in prioritizing funding decisions.
Award Budget	The combined budget for direct costs for the two year budget and project period may not exceed $100,000. No more than $50,000 direct costs may be requested in any single year. Applicable F&A costs should also be requested. Award funds shall be expended within 24 months of the Initial Issue Date listed on the Notice of Award.
Award Project Period	The total project period may not exceed 2 years. Funds will be provided in a single award with a 24-month budget and project period. No-cost extensions will not be available. Therefore the applicant must assure that the scope of work proposed and outlays of awarded funds can be completed within this 24-month period.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Eligibility is limited to research institutions located in the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant organizations must complete the following registrations as described in the SF424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.

• System for Award Management (SAM) must maintain an active entity registration (formerly CCR registration), to be renewed at least annually. Use the Sam.gov Manage Entity function to manage your entity registrations. See the Grants Registration User Guide at SAM.gov for additional information.
• Grants.gov
• eRA Commons

All Program Directors/Principal Investigators (PD(s)/PI(s)) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization.

All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least 6 weeks prior to the application due date.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

Individuals proposed as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) must be new or early stage investigators as defined by NIH New and Early Stage Investigator Policies.

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:

• To an RFA of an application that was submitted previously as an investigator-initiated application but not paid;
• Of an investigator-initiated application that was originally submitted to an RFA but not paid; or
• Of an application with a changed grant activity code.

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed research
• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
• Names of other key personnel
• Participating institution(s)
• Number and title of this funding opportunity

The letter of intent should be sent to:

Weihua Luo, PhD
Center for Scientific Review (CSR)
National Institutes of Health
6701 Rockledge Drive
Room 5114, MSC 7808
Bethesda, MD 20892 (20817-FedEx)
Telephone: 301-435-1170
Fax: 301-480-2241
Email: luow@mail.nih.gov

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Facilities and Other Resources: Provide a letter from the institution that verifies that pilot research data existed prior to the hurricane and that describes the extent of the damage, destruction or loss resulting from the hurricane, including staff time, research materials, resources, supplies, and preliminary data. The letter must confirm that the application does not request any funding that overlaps with FEMA, under a contract for insurance, or self insurance payments. The letter must be signed by an institutional Signing Official.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Due to the special monitoring and reporting requirements of the Disaster Relief Appropriations Act, the application must include a detailed R&R budget for all budget periods. Applications that include Modular Budgets will not be accepted. Applicants should disregard any submission warnings regarding the use of modular budgets in these applications.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy: Include a description of damages and loss that occurred as a result of Hurricane Sandy. The Research Strategy should describe the research planned and the type of data expected to be regenerated. The Research Strategy should also describe how the applicant will accommodate the resources in the event that major renovations or re-establishment of resources are required in order to perform the proposed research. A clear timeline for execution and completion must be included.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.

Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.

Applicants are responsible for viewing their application before the deadline in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Funds will be awarded in a single action using a 24-month budget and project period. Awarded funds shall be expended within 24-months of the Initial Issue Date listed on the Notice of Award. No-cost extensions will not be available.

Awards will be subject to quarterly financial and programmatic reporting requirements. Details for submitting these required reports will be provided in the Terms of Award.

Funds will be restricted so that they cannot duplicate costs reimbursed by FEMA, under a contract for insurance or self insurance. If during the period of the award a claim is paid which provides such duplication, the grantee will be required to pay back the funds to the NIH.

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.

Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for theSystem for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by NIH programmatic staff. Applications that are incomplete and/or nonresponsive will not be reviewed.

Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

For this particular announcement, note the following:

For this FOA, extensive background material or preliminary information is not expected due to the loss of this preliminary data as a result of Hurricane Sandy. Accordingly, reviewers will focus their evaluation on the conceptual framework and the potential to significantly advance our knowledge or understanding of the research field. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?

If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.

Inclusion of Women, Minorities, and Children

When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the CSR, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

• May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
• Will receive a written critique.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

• Scientific and technical merit of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.
• Extent and severity of the damages on the research that is directly related to Hurricane Sandy.
• Ability for the scope of work proposed and funding outlays to be completed within the 24-month period.

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website. Awards will be subject to additional quarterly financial and programmatic reporting requirements. Details for submission of these required reports will be provided in the terms of award.

Funds will be awarded using a single 24-month budget and project period. Awarded funds shall be expended within 24-months of the Initial Issue Date listed on the Notice of Award. No-cost extensions will not be available. All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. With the exceptions noted above, for these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Awards will be subject to additional quarterly financial and programmatic reporting requirements. The NIH will closely monitor all grants.

Cooperative Agreement Terms and Conditions of Award

Not Applicable

Quarterly financial and programmatic reporting is required of all grantees. Awards may be subject to additional reporting requirements as determined by HHS.

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: GrantsInfo@nih.gov

eRA Commons Help Desk (Questions regarding eRA Commons registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: commons@od.nih.gov

Bernard Talbot, M.D. PhD
National Center for Advancing Translational Sciences (NCATS)
Phone: 301-435-0793
Email: talbotb@mail.nih.gov

John Williamson, PhD
National Center for Complementary and Alternative Medicine (NCCAM)
Phone: 301-496-2583
Email: williamsonjs@mail.nih.gov

Stephen T. White, PhD
National Cancer Institute (NCI)
Phone: 240-276-6180
Email: SW219T@nih.gov

Lisa A. Neuhold, PhD
National Eye Institute (NEI)
Phone: 301-451-2020
Email: lneuhold@mail.nih.gov

Bettie J. Graham, PhD
National Human Genome Research Institute (NHGRI)
Phone: 301-435-7858
Email: grahamb@odder.nhgri.nih.gov

Robert Musson, PhD
National Heart, Lung and Blood Institute (NHLBI)
Phone: 301-435-0261
Email: mussonr@mail.nih.gov

James Griffin, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phone: 301/435-2307
Email: griffinj@mail.nih.gov

David Shurtleff, PhD
National Institute on Drug Abuse (NIDA)
Phone: 301-443-6480
Email: dshurtle@mail.nih.gov

Darren Sledjeski, PhD
National Institute of General Medical Sciences (NIGMS)
Phone: 301-594-0943
Email: Darren.Sledjeski@NIH.gov

Robin A. Barr, DPhil
National Institute on Aging (NIA)
Phone: 301-496-9322
Email: rb42h@nih.gov

Abraham P. Bautista, PhD
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phone 301-443-9737
Email: bautista@mail.nih.gov

Patricia Haggerty, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 301-451-2615
Email: haggertp@nih.gov

Laura K. Moen, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-451-6515
Email: moenl@mail.nih.gov

Christina H Liu, PhD, PE
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Phone: 301-451-7638
Email: liuch2@mail.nih.gov

Judith A. Cooper, PhD
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phone: 301-496-5061
Email: Cooperj@nidcd.nih.gov

Lillian Shum, PhD
National Institute of Dental and Craniofacial Research (NIDCR)
Phone: 301-594-0618
Email: ShumL@mail.nih.gov

Teresa L. Z. Jones, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phone: 301 435-2996
Email: jonester@mail.nih.gov

Cindy Lawler, PhD
National Institute of Environmental Health Sciences (NIEHS)
Phone: 919-316-4671
Email: lawler@niehs.nih.gov

Rebecca Claycamp, MS
National Institute of Mental Health (NIMH)
Phone: 301-443-2811
Email: rclaycam@mail.nih.gov

Nathan Stinson, Jr., MD, PhD, MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-594-8704
Email: stinsonn@mail.nih.gov

David F Owens, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 301-496-1447
Email: do47h@nih.gov

Karen Huss, PhD, RN
National Institute of Nursing Research (NINR)
Phone: 301-594-5970
Email: hussk@mail.nih.gov

Hua-Chuan Sim, MD
National Library of Medicine (NLM)
Phone: 301-594-4882
Email: simh@mail.nih.gov

John D. Harding, PhD
Office of Research Infrastructure Programs (ORIP)
Phone: 301-435-0776
Email: hardingj@mail.nih.gov

Barbara Sina
Fogarty International Center (FIC)
Phone: 301-402-9467
Email: sinab@mail.nih.gov

Weihua Luo, PhD
Center for Scientific Review (CSR)
Telephone: 301-435-1170
Email: luow@mail.nih.gov

Gloria Berrios
National Center for Advancing Translational Sciences (NCATS)
Phone: 301-435-0875
Email: berriosgl@mail.nih.gov

Shelley M. Carow
National Center for Complementary and Alternative Medicine (NCCAM)
Phone: 301-594-3788
Email: carows@mail.nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Phone: 240-276-6277
Email: Crystal.Wolfrey@nih.gov

William W. Darby
National Eye Institute (NEI)
Phone: 301-451-2020
Email: darbyw@mail.nih.gov

Cheryl Chick
National Human Genome Research Institute (NHGRI)
Phone: 301-435-7858
Email: chickc@mail.nih.gov

Jayanthi Regunathan
National Heart, Lung and Blood Institute (NHLBI)
Phone: 301-435-0175
Email: jayanthi.regunathan@nih.gov

Bryan S. Clark, MBA
National Institute of Child Health and Human Development (NICHHD)
Phone: 301-435-6975
Email: Clarkb1@mail.nih.gov

Earl C. Melvin
National Institute of General Medical Sciences (NIGMS)
Phone: 301-594-3912
Email: melvine@mail.nih.gov

Traci Lafferty
National Institute on Aging (NIA)
Phone: 301-496-8987
Email: laffertt@nia.nih.gov

Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phone: 301-443-4704
Email: Judy.Fox@nih.gov

Gregory P. Smith
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 301- 402-5540
Email: gs225y@nih.gov

Andrew Jones
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-435-0610
Email: jonesan@mail.nih.gov

James Huff
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Phone: 301-451-4786
Email: huffj@mail.nih.gov

Christopher Myers
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phone: 301-435-0713
Email: myersc@nidcd.nih.gov

Dede Rutberg
National Institute of Dental and Craniofacial Research (NIDCR)
Phone: 301-594-4798
Email: rutbergd@mail.nih.gov

Bob Pike
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phone: 301-594-8854
Email: pikera@niddk.nih.gov

Dorothy Duke
National Institute of Environmental Health Sciences (NIEHS)
Phone: 919- 541-2749
Email: duke2@niehs.nih.gov

Rebecca Claycamp, M.S.
National Institute of Mental Health (NIMH)
Phone: 301-443-2811
Email: rclaycam@mail.nih.gov

Priscilla Grant, JD
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-594-8412
Email: grantp@mail.nih.gov

Tijuanna Decoster
National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 301-496-9231
Email: decostert@mail.nih.gov

Ron Wertz
National Institute of Nursing Research (NINR)
Phone: 301-594-2807
Email: Wertzr@mail.nih.gov

Amy Keener
National Library of Medicine (NLM)
Phone: 301-496-6131
Email: akeener@mail.nih.gov

Liz Cleveland Whittington
Fogarty International Center (FIC)
Phone: 301-451-6830
Email: elizabeth.cleveland@nih.gov

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.